Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

NCT04645160 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04645160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04645160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 4, 2022
Completion date
December 31, 2029
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct neoplasm, biliary tract malignancy, cholangiocarcinoma